Outcome of hypertension management in Asian Americans

Archives of Internal Medicine

Volumn 157, Issue 12, 1997, Pages 1345-1348

  Hui, Ka Kit ^a,b   Pasic, Jagoda ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; ASIAN AMERICAN; BLOOD PRESSURE REGULATION; DRUG RESPONSE; ETHNIC DIFFERENCE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 1842368501     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.12.1345     Document Type: Article

References (16)

1. Tamir A, Cachola S. Hypertension and other cardiovascular risk factors. In: Zane NWS, Takeuchi DT, Young KNJ, eds. Confronting Critical Health Issues of Asian and Pacific Islander Americans. Thousand Oaks, Calif; Sage Publications International, Educational, and Professional Publisher; 1994.
2. Jones DW. Hypertension in East Asia. Am J Hypertens. 1995;8:111S-114S.
3. Kalow W. Pharmacoanthropology: drug metabolism. Fed Proc. 1984;43:2326-2331.
4. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJJ. Racial differences in drug response: altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med. 1989;320:565-570.
5. Zhou HH, Adedoyin A, Wilkinson GR. Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther. 1990;48:10-17.
6. Horai Y, Nakano M, Tkashi I, et al. Metoprolol and mephenytoin oxidation polymorphism in Far Eastern oriental subjects: Japanese versus Mainland Chinese. Clin Pharmacol Ther. 1989;46:198-207.
7. Lou YC, Ying L, Bertilsson L, Sjoqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet. 1987;2:852-853.
8. Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1993;153:154-183.
9. US Department of Commerce. Race and Hispanic Origin: 1990 Census Profile. Washington, DC: US Bureau of the Census; 1991.
10. Stavig GR, Igra A, Leonard AR. Hypertension among Asians and Pacific Islanders in California. Am J Epidemiol. 1984;119:677-691.
11. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988;148:1023-1038.
12. Ogihara T, Goto Y, Yoshinaga K, et al. Dose-effect relationship of carvedilol in essential hypertension. Drugs. 1988;36(suppl 6):75-81.
13. Cesaris RD, Assereto R, Chiaraffa R, et al. Efficacy of carvedilol: a new vasodilating beta-blocker in hypertensive patients. Cardiovasc Drugs Ther. 1987;1:225.
14. Tomlinson B, Woo J, Critchley JAJH. Isradipine treatment for hypertension in general practice in Hong Kong. Chin Med J. 1992;105:446-450.
15. Jones DW, Sands CD. Treatment of essential hypertension in Asians: enalapril as monotherapy versus combination therapy with hydrochlorothiazide. Pharmacotherapy. 1991;11:127-130.
16. Wood AJJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet. 1991;20:350-373.